Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTSI, p16) in superficial bladder cancer detected by fluorescence in situ hybridization

M. Balázs, Peter Carroll, Russell Kerschmann, Guido Sauter, Frederic M. Waldman

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Deletion of all or part of chromosome 9 is a well-described genetic alteration in bladder tumors. It has been proposed that inactivation of a tumor-suppressor gene on chromosome 9 is an important event in tumor development. Recent reports have supported cyclin-dependent kinase inhibitor 2 (CDKN2, also known as MTSI, INK4, p16) at 9p21 as a candidate tumorsuppressor gene in solid tumors. However, the prevalence of CDKN2 mutations in primary bladder tumors has been controversial. Therefore, we applied gene-specific probes for CDKN2 and the interferon alpha gene (IFNA), also located at 9p21, to characterize further the genomic deletions at this locus in bladder cancer. Seventeen superficial (pTa or pTI) bladder tumor specimens were examined for gene deletion by fluorescence in situ hybridization. Dual-labeling hybridization with a repetitive pericentromeric probe for chromosome 9 and a gene-specific probe for CDKN2 was performed to characterize the gene copy number in relation to the chromosome 9 copy number on a cell-by-cell basis. Homozygous deletion for CDKN2 without homozygous IFNA deletion was found in 5 of 17 tumors tested. Both genes were deleted in one additional case, and one tumor showed deletion of IFNA without deletion of CDKN2. Homozygous deletion at the 9p21 locus was found only in tumors having monosomy for the chromosome 9 centrorneric signal. These results indicate that the homozygous deletion of the CDKN2 gene is a frequent and early event in superficial bladder cancer.

Original languageEnglish
Pages (from-to)84-89
Number of pages6
JournalGenes Chromosomes and Cancer
Volume19
Issue number2
DOIs
Publication statusPublished - 1997

Fingerprint

Cyclin-Dependent Kinase 2
Chromosomes, Human, Pair 9
Fluorescence In Situ Hybridization
Urinary Bladder Neoplasms
Gene Deletion
Interferon-alpha
Genes
Neoplasms
p16 Genes
Monosomy
Gene Dosage
Tumor Suppressor Genes
Mutation

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTSI, p16) in superficial bladder cancer detected by fluorescence in situ hybridization. / Balázs, M.; Carroll, Peter; Kerschmann, Russell; Sauter, Guido; Waldman, Frederic M.

In: Genes Chromosomes and Cancer, Vol. 19, No. 2, 1997, p. 84-89.

Research output: Contribution to journalArticle

@article{923c689089a24db0ba120672279e12aa,
title = "Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTSI, p16) in superficial bladder cancer detected by fluorescence in situ hybridization",
abstract = "Deletion of all or part of chromosome 9 is a well-described genetic alteration in bladder tumors. It has been proposed that inactivation of a tumor-suppressor gene on chromosome 9 is an important event in tumor development. Recent reports have supported cyclin-dependent kinase inhibitor 2 (CDKN2, also known as MTSI, INK4, p16) at 9p21 as a candidate tumorsuppressor gene in solid tumors. However, the prevalence of CDKN2 mutations in primary bladder tumors has been controversial. Therefore, we applied gene-specific probes for CDKN2 and the interferon alpha gene (IFNA), also located at 9p21, to characterize further the genomic deletions at this locus in bladder cancer. Seventeen superficial (pTa or pTI) bladder tumor specimens were examined for gene deletion by fluorescence in situ hybridization. Dual-labeling hybridization with a repetitive pericentromeric probe for chromosome 9 and a gene-specific probe for CDKN2 was performed to characterize the gene copy number in relation to the chromosome 9 copy number on a cell-by-cell basis. Homozygous deletion for CDKN2 without homozygous IFNA deletion was found in 5 of 17 tumors tested. Both genes were deleted in one additional case, and one tumor showed deletion of IFNA without deletion of CDKN2. Homozygous deletion at the 9p21 locus was found only in tumors having monosomy for the chromosome 9 centrorneric signal. These results indicate that the homozygous deletion of the CDKN2 gene is a frequent and early event in superficial bladder cancer.",
author = "M. Bal{\'a}zs and Peter Carroll and Russell Kerschmann and Guido Sauter and Waldman, {Frederic M.}",
year = "1997",
doi = "10.1002/(SICI)1098-2264(199706)19:2<84::AID-GCC3>3.0.CO;2-W",
language = "English",
volume = "19",
pages = "84--89",
journal = "Genes Chromosomes and Cancer",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTSI, p16) in superficial bladder cancer detected by fluorescence in situ hybridization

AU - Balázs, M.

AU - Carroll, Peter

AU - Kerschmann, Russell

AU - Sauter, Guido

AU - Waldman, Frederic M.

PY - 1997

Y1 - 1997

N2 - Deletion of all or part of chromosome 9 is a well-described genetic alteration in bladder tumors. It has been proposed that inactivation of a tumor-suppressor gene on chromosome 9 is an important event in tumor development. Recent reports have supported cyclin-dependent kinase inhibitor 2 (CDKN2, also known as MTSI, INK4, p16) at 9p21 as a candidate tumorsuppressor gene in solid tumors. However, the prevalence of CDKN2 mutations in primary bladder tumors has been controversial. Therefore, we applied gene-specific probes for CDKN2 and the interferon alpha gene (IFNA), also located at 9p21, to characterize further the genomic deletions at this locus in bladder cancer. Seventeen superficial (pTa or pTI) bladder tumor specimens were examined for gene deletion by fluorescence in situ hybridization. Dual-labeling hybridization with a repetitive pericentromeric probe for chromosome 9 and a gene-specific probe for CDKN2 was performed to characterize the gene copy number in relation to the chromosome 9 copy number on a cell-by-cell basis. Homozygous deletion for CDKN2 without homozygous IFNA deletion was found in 5 of 17 tumors tested. Both genes were deleted in one additional case, and one tumor showed deletion of IFNA without deletion of CDKN2. Homozygous deletion at the 9p21 locus was found only in tumors having monosomy for the chromosome 9 centrorneric signal. These results indicate that the homozygous deletion of the CDKN2 gene is a frequent and early event in superficial bladder cancer.

AB - Deletion of all or part of chromosome 9 is a well-described genetic alteration in bladder tumors. It has been proposed that inactivation of a tumor-suppressor gene on chromosome 9 is an important event in tumor development. Recent reports have supported cyclin-dependent kinase inhibitor 2 (CDKN2, also known as MTSI, INK4, p16) at 9p21 as a candidate tumorsuppressor gene in solid tumors. However, the prevalence of CDKN2 mutations in primary bladder tumors has been controversial. Therefore, we applied gene-specific probes for CDKN2 and the interferon alpha gene (IFNA), also located at 9p21, to characterize further the genomic deletions at this locus in bladder cancer. Seventeen superficial (pTa or pTI) bladder tumor specimens were examined for gene deletion by fluorescence in situ hybridization. Dual-labeling hybridization with a repetitive pericentromeric probe for chromosome 9 and a gene-specific probe for CDKN2 was performed to characterize the gene copy number in relation to the chromosome 9 copy number on a cell-by-cell basis. Homozygous deletion for CDKN2 without homozygous IFNA deletion was found in 5 of 17 tumors tested. Both genes were deleted in one additional case, and one tumor showed deletion of IFNA without deletion of CDKN2. Homozygous deletion at the 9p21 locus was found only in tumors having monosomy for the chromosome 9 centrorneric signal. These results indicate that the homozygous deletion of the CDKN2 gene is a frequent and early event in superficial bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=0343923480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0343923480&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1098-2264(199706)19:2<84::AID-GCC3>3.0.CO;2-W

DO - 10.1002/(SICI)1098-2264(199706)19:2<84::AID-GCC3>3.0.CO;2-W

M3 - Article

VL - 19

SP - 84

EP - 89

JO - Genes Chromosomes and Cancer

JF - Genes Chromosomes and Cancer

SN - 1045-2257

IS - 2

ER -